34 showed that CLU appeared to be both a biomarker associated with ovarian cancer and a prognostic factor associated with shorter survival. Overexpression of CLU in ovarian cancer tissue samples was found more often in advanced stage disease (P = 0.0001) compared with earlier disease. In addition, average survival time in patients with CLU overexpression was significantly shorter than in those with normal CLU expression (P = 0.033). Here, CLU is linked to ovarian cancer.